natgillin/translations-raw huggingface dataset:
Do not give yourself a second dose without speaking to your healthcare provider. 
Ne dajte si še drugega odmerka, ne da bi se pogovorili z zdravnikom.
Look at the medicine through the viewing window on the syringe: 
Skozi okence za ogled v brizgi preglejte zdravilo:
Patients who continued on the same dose regimen received in the SOLO 1 and SOLO 2 studies (300 mg Q2W or 300 mg QW) showed the optimal effect in maintaining clinical response while efficacy for other dose regimens diminished in a dose-dependent manner. 
Bolniki, ki so uporabljali enako odmerno shemo kot v študijah SOLO 1 in SOLO 2 (300 mg vsak drugi teden ali 300 mg vsak teden), so glede vzdrževanja kliničnega odziva dosegli najboljši učinek; učinkovitost drugih odmernih shem se je zmanjševala od odmerka odvisno.
Table 5: Demographics and Baseline Characteristics of Asthma Trials 
Preglednica 5: Demografske in izhodiščne značilnosti v preskušanjih pri astmi
• Stomach except for the 5 cm around your belly button (navel). 
• Trebuh - razen 5 cm okrog popka.
Patients requiring a third controller were allowed to participate in this trial. 
V tem preskušanju so lahko sodelovali tudi bolniki, ki so potrebovali še tretje zdravilo za obvladovanje.
This should be taken into consideration to determine type 2 status in patients taking oral corticosteroids (see section 
To je treba upoštevati pri določanju statusa tipa 2 pri bolnikih, ki uporabljajo peroralne kortikosteroide (glejte poglavje 5.1).
% patients with EOS 
% bolnikov z diNO
Conjunctivitis occurred more frequently in atopic dermatitis patients who received dupilumab. 
Konjunktivitis je bil pri bolnikih z atopijskim dermatitisom, ki so prejemali dupilumab, pogostejši.
Carcinogenicity studies have not been conducted with dupilumab. 
Študij kancerogenosti z dupilumabom niso izvedli.
Remove 
Odstranite
Pharmacotherapeutic group: Other dermatological preparations, agents for dermatitis, excluding corticosteroids, ATC code: D11AH05 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: Druga zdravila za bolezni kože in podkožnega tkiva, učinkovine za zdravljenje dermatitisa, razen kortikosteroidov Oznaka ATC: D11AH05
If the carton needs to be removed permanently from refrigerator, the date of removal may be recorded on the outer carton. 
Če je treba škatlo trajno vzeti iz hladilnika, je mogoče datum, ko je bila vzeta iz hladilnika, zabeležiti na zunanji ovojnini.
The recommended dose of dupilumab for adolescent patients 12 to 17 years of age is specified in Table 1. 
Priporočeni odmerek dupilumaba za mladostnike od 12. do 17. leta starosti je prikazan v preglednici 1.
Among asthma patients frequency of conjunctivitis was low and similar between dupilumab and placebo (see section 
Pri bolnikih z astmo je bila pogostnost konjunktivitisa majhna ter pri dupilumabu in placebu podobna (glejte poglavje 4.4).
Patients randomised IGA 0 or 1b, % respondersc 
Randomizirani bolniki IGA 0 ali 1b, % odzivnihc
• Keep unused syringes in the original carton and store in the refrigerator between 2ºC and 8ºC. 
• Neuporabljene napolnjene injekcijske peresnike shranjujte v originalni škatli in v hladilniku na temperaturi od 2 do 8 °C.
Placebo 237 0.22 (14.2) ap-value <0.0001, bp-value = 0.0004, cp-value = 0.0008, dp-value = 0.0063, ep-value <0.0001 
Placebo 237 0,22 (14,2) ap-vrednost <0,0001, bp-vrednost = 0,0004, cp-vrednost = 0,0008, dp-vrednost = 0,0063, ep-vrednost <0,0001
The primary endpoint was change from baseline to week 12 in FEV1 (L). 
Primarni opazovani dogodek je bila sprememba FEV1 (l) od izhodišča do 12. tedna.
Gather supplies 
Zberite pribor
Eligible patients enrolled into this study had previous inadequate response to topical medication. 
Primerni bolniki, vključeni v to študijo, se predhodno niso zadostno odzvali na lokalna zdravila.
No dose adjustment is recommended for elderly patients (see section 5.2). 
Starejšim bolnikom odmerka ni treba prilagoditi (glejte poglavje 5.2).
Body Weight of Patient 
Bolnikova telesna masa
• Ask your healthcare professional to show you the right way to use the syringe before you inject for the first time. 
• Preden si prvič injicirate zdravilo, zdravnika prosite, naj vam pokaže, kako pravilno uporabljati brizgo.
PRO Treatment 
PRO Zdravljenje
In adolescents 12 years and older, it is recommended that Dupixent be administered by or under supervision of an adult. 
Priporočljivo je, da mladostnikom, starim 12 let ali več, zdravilo Dupixent injicira odrasla oseba oziroma da uporaba zdravila poteka pod nadzorstvom odrasle osebe.
After removing the 200 mg pre-filled syringe or pre-filled pen from the refrigerator, it should be allowed to reach room temperature by waiting for 30 min before injecting Dupixent. 
Potem, ko je 200 mg napolnjena injekcijska brizga ali napolnjeni injekcijski peresnik vzet iz hladilnika, je treba pustiti, da doseže sobno temperaturo, in sicer tako, da se jo pusti na sobni temperaturi 30 minut pred injiciranjem zdravila Dupixent.
Number of patients with HADS-anxiety ≥ 8 or HADSdepression ≥ 8 at baseline Patients achieving HADS-anxiety and HADSdepression < 8, 
odzivnih Število bolnikov z izhodiščno oceno HADSanksioznost ≥ 8 ali HADSdepresija ≥ 8 Bolniki, ki so dosegli oceno HADSanksioznost in HADSdepresija < 8,
Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. 
Dupilumab je rekombinantno človeško monoklonsko protitelo IgG4, ki zavira signalizacijo z interlevkinom-4 in interlevkinom -13.
Dupilumab should not be injected into skin that is tender, damaged or has bruises or scars. 
Dupilumaba se ne sme injicirati v kožo, ki je občutljiva, poškodovana, ima modrice ali je zabrazgotinjena.
Do not use the syringe if it has been damaged. 
Ne uporabite brizge, če je poškodovana.
Insert the needle into the fold of skin at roughly a 45º angle. 
Zabodite iglo do konca v kožno gubo pod kotom približno 45 stopinj.
If you use more Dupixent than you should or the dose has been given too early, talk to your doctor, pharmacist or nurse. 
Če ste uporabili večji odmerek zdravila Dupixent, kot bi smeli Če uporabite večji odmerek zdravila Dupixent, kot bi smeli, ali če odmerek uporabite prezgodaj, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Dupilumab compared with placebo was evaluated in 107 adolescent and 1,795 adult patients with persistent asthma on a medium-to-high dose inhaled corticosteroid (ICS) and a second controller medication. 
Dupilumab so v primerjavi s placebom ocenili pri 107 mladostnikih in 1.795 odraslih s persistentno astmo, ki so prejemali srednje velik ali velik odmerek inhalacijskega kortikosteroida (IKS) še eno zdravilo za obvladovanje.
Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy. 
Zmanjšanje odmerka kortikosteroida lahko spremljajo sistemski odtegnitveni simptomi oziroma lahko takšno zmanjšanje razkrije bolezni, ki jih zdravljenje s sistemskimi kortikosteroidi pred tem zaviralo.
In DRI12544 and QUEST, the pre-specified subgroup analyses included blood eosinophils ≥ 150 and ≥ 300 cells/mcL, FeNO ≥ 25 and ≥ 50 ppb. 
V študijah DRI12544 in QUEST so vnaprej določene analize podskupin obsegale eozinofilce v krvi ≥ 150 in ≥ 300 celic/mcl ter diNO ≥ 25 in ≥ 50 ppb.
Percent of patients whose IGA response at week 36 was maintained within 1 point of baseline in the subset of patients with IGA (0,1) at baseline, n (%) Percent of patients with IGA (0,1) at week 36 in the subset of patients with IGA (0,1) at baseline, n (%) Percent of patients whose peak pruritus 
točke v primerjavi z izhodiščem, v podskupini bolnikov, ki so izhodiščno imeli IGA (0,1), n (%) Odstotek bolnikov z IGA (0,1) po 36 tednih v podskupini bolnikov, ki so izhodiščno imeli IGA (0,1), n (%)
The long-term safety of dupilumab was assessed in an open-label extension study in patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD-1434). 
Dolgoročno varnost dupilumaba so ocenili v odprtem podaljšanju študije pri bolnikih z zmernim do hudim atopijskim dermatitisom, starih od 12 do 17 let (študija AD-1434).
The results for VENTURE by baseline biomarkers are presented in the Table 17. 
Rezultati v študiji VENTURE po izhodiščnih bioloških označevalcih so prikazani v preglednici 17.
In the subgroup of patients resembling the CAFE study population within the 52 week CHRONOS study, 69.6 % of dupilumab 300 mg Q2W-treated patients reached EASI-75 vs 18.0 % placebo-treated patients at week 16, and 52.4 % of dupilumab 300 mg Q2W-treated vs 18.6 % placebo-treated at week 52. 
V podskupini bolnikov, ki so bili podobni populaciji študije CAFE, je v 52-tedenski študiji CHRONOS po 16 tednih doseglo EASI-75 69,6 % bolnikov, ki so prejemali 300 mg dupilumaba vsak drugi teden, in 18,0 % bolnikov, ki so prejemali placebo, po 52 tednih pa 52,4 % bolnikov, ki so prejemali 300 mg dupilumaba vsak drugi teden, in 18,6 % bolnikov, ki so prejemali placebo.
After use, place the pre-filled syringe into a puncture-resistant container and discard as required by local regulations. 
Po uporabi je treba dati napolnjeno injekcijsko brizgo v vsebnik, odporen proti prebadanju, in zavreči, kot zahtevajo lokalnimi predpisi.
Do not use the pre-filled pen if the window is yellow. 
Napolnjenega injekcijskega peresnika ne uporabite, če je okence rumeno.
During a reproductive toxicology study conducted in monkeys, using a surrogate antibody specific to the monkey IL-4Rα, no fetal abnormalities were observed at dosages that saturate the IL-4Rα. 
Med študijo reproduktivne toksičnosti pri opicah z uporabo nadomestnih protiteles, specifičnih za opičji IL-4Rα, med uporabo odmerkov, ki zasitijo IL-4Rα, niso opažali nenormalnosti pri plodovih.
Patients were also permitted to use topical calcineurin inhibitors (TCI). 
Bolniki so smeli uporabljati tudi lokalne zaviralce kalcinevrina.
Dupilumab compared with placebo was evaluated in adult patients with moderate to severe asthma on a medium-to-high dose inhaled corticosteroid and a long acting beta agonist. 
Dupilumab so v primerjavi s placebom ocenili pri odraslih bolnikih z zmerno do hudo astmo, ki so prejemali srednje velik ali velik odmerek inhalacijskega kortikosteroida in dolgodelujoč agonist beta.
Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment for atopic dermatitis. 
Pri bolnikih, ki se v 16 tednih zdravljenja atopijskega dermatitisa ne odzovejo, je treba razmisliti o prenehanju zdravljenja.
How to use Dupixent 
Kako uporabljati zdravilo Dupixent
Pruritus NRS 
Ocena srbenja NRS,
In this study, 53.1 % of patients had a baseline IGA score of 3 and 46.9 % of patients had a baseline IGA of 4 and 33.6 % of patients received prior systemic immunosuppressants. 
V tej študiji je imelo 53,1 % bolnikov izhodiščno oceno IGA 3 in 46,9 % bolnikov izhodiščno oceno IGA 4, 33,6 % bolnikov pa je predhodno prejemalo sistemske imunosupresive.
Pruritus NRS (>4-point improvement), % respondersc 
Ocena srbenja NRS (izboljšanje za > 4 točke),
The safety and efficacy of dupilumab in children with atopic dermatitis below the age of 12 years have not been established (see section 5.2). 
Varnost in učinkovitost dupilumaba pri otrocih z atopijskim dermatitisom do 12. leta starosti nista ugotovljeni (glejte poglavje 5.2).
After use, place the pre-filled syringe or the pre-filled pen into a puncture-resistant container and discard as required by local regulations. 
Po uporabi je treba dati napolnjeno injekcijsko brizgo ali napolnjen injekcijski peresnik v vsebnik, odporen proti prebadanju, in zavreči, kot zahtevajo lokalnimi predpisi.
• Let your skin dry before injecting. 
• Pustite, da se koža pred injiciranjem posuši.
The long-term safety profile of dupilumab observed in adolescents was consistent with that seen in adults with atopic dermatitis. 
Dolgoročne varnostne značilnosti dupilumaba pri mladostnikih so se skladale s tistimi pri odraslih z atopijskim dermatitisom.
• Store pre-filled pens in the original carton to protect it from light. 
• Napolnjene injekcijske peresnike shranjujte v originalni škatli za zagotovitev zaščite pred svetlobo.
• Do not try to put the yellow cap back on the pre-filled pen. 
• Ne poskušajte rumenega pokrovčka namestiti nazaj na napolnjeni injekcijski peresnik.
Number of patients with HADS-anxiety 
Število bolnikov z izhodiščno oceno HADS
Very limited data are available in patients with severe renal impairment (see section 5.2). 
Podatkov o bolnikih s hudo okvaro ledvic je zelo malo (glejte poglavje 5.2).
• Do not use the syringe if it has been dropped on a hard surface or damaged. 
• Ne uporabite brizge, če vam je padla na trdo površino ali je poškodovana.
• Do not touch the plunger rod until you are ready to inject. 
• Ne dotikajte se bata, dokler niste pripravljeni za injiciranje.
Dupilumab-treated patients had a greater mean initial increase from baseline in eosinophil count compared to patients treated with placebo. 
Pri bolnikih, ki so prejemali dupilumab, je bil povprečni začetni porast števila eozinofilcev v primerjavi z izhodiščem večji kot pri bolnikih, ki so prejemali placebo.
Step 11: Release and Remove 
11. korak: Sprostite in izvlecite iglo
respondersd, e 
% odzivnihd, e
Number of patients with baseline pruritus NRS score > 4 
Število bolnikov z izhodiščno oceno srbenja NRS > 4
A larger percentage of patients randomised to placebo needed rescue treatment (topical corticosteroids, systemic corticosteroids, or systemic non-steroidal immunosuppressants) as compared to the dupilumab group (58.8% and 20.7%, respectively). 
Rešilno zdravljenje (lokalne kortikosteroide, sistemske kortikosteroide ali sistemske nesteroidne imunosupresive) je potreboval večji odstotek bolnikov v skupini s placebom (58,8 %) kot v skupini z dupilumabom (20,7 %).
Let your skin dry before injecting. 
Pustite, da se koža pred injiciranjem posuši.
Recommended dose in adult and adolescent patients with asthma For asthma, the recommended dose of Dupixent for adult and adolescents patients (12 years of age and older) is: 
Priporočeni odmerek za odrasle in mladostnike z astmo Za astmo je priporočeni odmerek zdravila Dupixent za odrasle in mladostnike (stare 12 let ali več):
Hold the syringe in the middle of the syringe body with the needle pointing away from you and pull off the needle cap. 
Brizgo primite na sredi telesa brizge in tako, da je igla usmerjena proč od vas, in snemite pokrovček igle.
The safety and efficacy of dupilumab in children with severe asthma below the age of 12 years have not been established (see section 5.2). 
Varnost in učinkovitost dupilumaba nista ugotovljeni pri otrocih s hudo astmo, mlajših od 12 let (glejte poglavje 5.2).
Dupilumab can be used with or without topical corticosteroids. 
Dupilumab je mogoče uporabljati z lokalnimi kortikosteroidi ali brez njih.
Anaphylactic reaction has been reported very rarely in the asthma development program (see section 4.4). 
V programu razvoja pri astmi so zelo redko poročali o anafilaktični reakciji (glejte poglavje 4.4).
Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab-treated and placebo-treated patients. 
Odzivi protiteles na cepivo proti tetanusu in na meningokokno polisaharidno cepivo so bili pri bolnikih, ki so prejemali dupilumab, podobni kot pri tistih, ki so prejemali placebo.
• Do not remove the yellow cap until just before you give the injection. 
• Rumeni pokrovček odstranite šele tik pred injiciranjem.
If somebody else administers the injection, the upper arm can also be used. 
Če bolniku zdravilo injicira kdo drug, lahko uporabi tudi nadlaket.
Patients with comorbid asthma should be monitored carefully following discontinuation of dupilumab. 
Bolnike s pridruženo astmo je treba po prenehanju zdravljenja z dupilumabom skrbno nadzirati.
Do not remove the yellow cap until you are ready to inject. 
Ne odstranite rumenega pokrovčka, dokler niste pripravljeni za injiciranje.
The data gathered from this study did not indicate clinically relevant effects of dupilumab on CYP1A2, CYP3A, CYP2C19, CYP2D6, or CYP2C9 activity. 
CYP1A2, CYP3A4, CYP2C19, CYP2D6 ali CYP2C9.
Select the injection site. 
Izberite mesto injiciranja
Approximately 5 % of patients in the placebo groups in the 52 week studies were also positive for antibodies to dupilumab; approximately 2 % exhibited persistent ADA response and approximately 1% had neutralizing antibodies. 
V 52-tedenskih študijah je bilo za protitelesa proti dupilumabu pozitivnih tudi približno 5 % bolnikov v skupinah s placebom; približno 2 % bolnikov sta imela trajen odziv ADA in približno 1 % je imel nevtralizacijska protitelesa.
Do not inject into skin that is tender, damaged, bruised or scarred. 
Ne injicirajte v kožo, ki je občutljiva, poškodovana, podpluta ali zabrazgotinjena.
In these studies, 51.6 % of patients had a baseline IGA score of 3 (moderate AD), 48.3 % of patients had a baseline IGA of 4 (severe AD) and 32.4 % of patients had received prior systemic immunosuppressants. 
V teh študijah je imelo 51,6 % bolnikov izhodiščno oceno IGA 3 (zmeren AD), 48,3 % bolnikov je imelo izhodiščno oceno IGA 4 (hud AD) in 32,4 % bolnikov je predhodno prejemalo sistemske imunosupresive.
Step 10: Push 
10. korak: Potisnite bat
The primary endpoints were the annualized rate of severe exacerbation events during the 52-week placebo controlled period and change from baseline in pre-bronchodilator FEV1 at week 12 in the overall population (unrestricted by minimum baseline eosinophils or other type 2 inflammatory biomarkers) and subgroups based on baseline blood eosinophils and FeNO. 
Primarna opazovana dogodka sta bila letni delež hudih poslabšanj med 52-tedenskim s placebom kontroliranim obdobjem in sprememba FEV1 pred bronhodilatatorjem po 12 tednih v primerjavi z izhodiščem v celotni populaciji (ki ni bila omejena z najmanjšo izhodiščno ravnjo eozinofilcev ali drugih bioloških označevalcev tipa 2) in v podskupinah glede na izhodiščno število eozinofilcev v krvi in diNO.
In the monotherapy studies (SOLO 1 and SOLO 2), across all treatment groups, the mean age was 38.3, the mean weight was 76.9 kg, 42.1% were female, 68.1% were white, 21.8% were Asian, and 6.8% were black. 
Izhodiščne značilnosti V študijah monoterapije (SOLO 1 in SOLO 2) je bila v vseh terapevtskih skupinah skupaj povprečna starost 38,3 leta, povprečna telesna masa 76,9 kg, 42,1 % je bilo žensk, 68,1 % je bilo belcev, 21,8 %
Placebo ap-value = 0.0003, bp-value = 0.0001, cp-value = 0.0116, dp-value = 0.0024, ep-value <0.0001 
Placebo ap-vrednost = 0,0003, bp-vrednost = 0,0001, cp-vrednost = 0,0116, dp-vrednost = 0,0024, ep-vrednost <0,0001
Table 2: List of adverse reactions in atopic dermatitis MedDRA System 
Preglednica 2: Seznam neželenih učinkov pri atopijskem dermatitisu
Recommended dose in adolescents with atopic dermatitis The recommended dose of Dupixent for adolescents (12 to 17 years of age) with atopic dermatitis is based on body weight: 
Priporočeni odmerek za mladostnike z atopijskim dermatitisom Priporočeni odmerek zdravila Dupixent za mladostnike (stare od 12 do 17 let) z atopijskim dermatitisom je odvisen od telesne mase:
Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. 
Dupilumab je popolnoma humanomonoklonsko protitelo proti receptorju alfa interlevkina (IL)-4, ki zavre signalizacijo IL-4/IL-13; dupilumab je pridobljen v celicah jajčnika kitajskega hrčka s tehnologijo rekombinantne DNA.
• Do not use the pre-filled pen if the yellow cap is missing or not securely attached. 
• Ne uporabite napolnjenega injekcijskega peresnika, če rumeni pokrovček manjka ali ni trdno nameščen.
Number of patients with baseline pruritus NRS score ≥ 4 
Število bolnikov z izhodiščno oceno srbenja NRS ≥ 4
Improvements in ACQ-5 and AQLQ(S) were observed as early as week 2 and maintained for 24 weeks in DRI12544 study and 52 weeks in QUEST study. 
Izboljšanja ACQ-5 in AQLQ(S) so opazili že po 2 tednih in so se ohranila 24 tednov v študiji DRI12544 in 52 tednov v študiji QUEST.
A total of 210 patients with oral corticosteroid-dependent asthma receiving high-dose inhaled corticosteroids plus up to two additional controllers were enrolled (VENTURE). 
bolnikov z astmo, odvisno od peroralnih kortikosteroidov, ki so prejemali velike odmerke inhalacijskih kortikosteroidov in do dve dodatni zdravili za obvladovanje (VENTURE).
• Keep the pre-filled pen(s) and all medicines out of the reach of children. 
• Napolnjene injekcijske peresnike in vsa zdravila shranjujte nedosegljivo otrokom!
Dupixent is also used with other asthma medicines for the maintenance treatment of severe asthma in adults and adolescents (12 years of age and older) whose asthma is not controlled with their current asthma medicines. 
Zdravilo Dupixent se uporablja tudi z drugimi zdravili za astmo za vzdrževalno zdravljenje hude astme pri odraslih in mladostnikih (starih 12 let ali več), ki bolezni nimajo urejene s svojimi trenutnimi zdravili za astmo.
For clinical data in adults with atopic dermatitis please refer to the dupilumab 300 mg Summary of Product Characteristics. 
Za klinične podatke o odraslih z atopijskim dermatitisom glejte povzetek glavnih značilnosti zdravila za
Additional secondary endpoints included mean change from baseline to week 16 in the POEM and CDLQI scores. 
Med dodatnimi sekundarnimi opazovanimi dogodki sta bili povprečni spremembi ocen POEM in CDLQI od izhodišča do 16. tedna.
Duration of Asthma (years), mean ± SD Never smoked, (%) 
odklon Nikoli kadili (%)
Table 1: Dose of dupilumab for subcutaneous administration in adolescent patients 12 years to 17 years of age with atopic dermatitis Body Weight of Patient 
Preglednica 1: Odmerek dupilumaba za subkutano uporabo pri mladostnikih z atopijskim dermatitisom od 12. do 17. leta starosti Bolnikova telesna masa
CHRONOS at Week 52 
CHRONOS po 52 tednih
At Week 52 
52. teden
Dupixent is a clear to slightly opalescent, colourless to pale yellow solution supplied in a glass prefilled syringe with or without needle shield. 
Zdravilo Dupixent je bistra do rahlo opalescentna, brezbarvna do bledo rumena raztopina v stekleni napolnjeni injekcijski brizgi s ali brez ščitnika igle.
Table 5: Efficacy results of dupilumab with concomitant TCSa at Week 16 and Week 52 in CHRONOS 
Preglednica 5: Rezultati učinkovitosti dupilumaba skupaj s sočasnimi LKSa po 16. in 52. tednih v študiji CHRONOS
The absolute bioavailability of dupilumab following a SC dose is similar between AD and asthma patients, ranging between 61% and 64 %, as determined by a population pharmacokinetics (PK) analysis. 
S populacijsko farmakokinetično (FK) analizo ocenjena absolutna biološka uporabnost dupilumaba je podobna pri pri bolnikih z atopijskim dermatitisom kot pri bolnikih z astmo in znaša po subkutanem odmerku med 61% in 64 %.
Do not put the yellow cap back on the pre-filled pen after you have removed it. 
Ne nameščajte rumenega pokrovčka nazaj na napolnjeni injekcijski peresnik, ko ste ga že sneli.
CHRONOS enrolled 740 patients (315 to placebo + topical corticosteroid (TCS), 106 to dupilumab 300 mg Q2W + TCS, and 319 to dupilumab 300 mg QW + TCS) and had a treatment period of 52 weeks. 
Študija CHRONOS je zajela 740 bolnikov (315 na placebu + lokalni kortikosteroid (LKS), 106 na dupilumabu 300 mg vsak drugi teden + LKS in 319 na dupilumabu 300 mg vsak teden + LKS); obdobje zdravljenja je trajalo 52 tednov.
• If you see any blood at the site, lightly dab a cotton ball or gauze pad. 
• Če na mestu injiciranja opazite nekaj krvi, s kosmom vate ali zložencem gaze rahlo pritisnite nanj.
Lay the syringe on a flat surface for at least 45 minutes and let it get to room temperature naturally. 
Brizgo za vsaj 45 minut položite na ravno površino in pustite, da se naravno segreje na sobno temperaturo.